Springworks Therapeutics Email Format
Biotechnology Research
・
201-500 employees
・
Stamford, CT, USA
Springworks Therapeutics is a commercial-stage biopharmaceutical company dedicated to developing and commercializing treatments for patients with rare tumors.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@springworkstx.com
Company Overview
Industry
Biotechnology Research
Founded
2017
Headquarters
Stamford, CT, USA
Revenue
$100M-$250M
FUNDING Stage
Public
Website
Key Executives
Saqib Islam (Chief Executive Officer), Francis (Frank) I. Perier, Jr. (Chief Financial Officer), Badreddin Edris (Chief Operating Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Springworks Therapeutics?
Springworks Therapeutics uses the firstinitiallast format, so Jane Smith would be jsmith@springworkstx.com.
What FDA-approved medicines does Springworks Therapeutics currently market?
Springworks Therapeutics markets two FDA-approved rare oncology medicines: OGSIVEO (nirogacestat) for adults with desmoid tumors and GOMEKLI (mirdametinib) for adult and pediatric patients with NF1-associated plexiform neurofibromas.
How can I find and verify a Springworks Therapeutics contact's email address?
Since Springworks Therapeutics follows the firstinitiallast format at springworkstx.com, you can construct a likely address from a contact's name and confirm it using a tool like Clay, which can verify deliverability and enrich additional contact details.
Who leads Springworks Therapeutics as CEO?
Saqib Islam serves as Chief Executive Officer of Springworks Therapeutics, with Francis (Frank) I. Perier, Jr. as Chief Financial Officer and Badreddin Edris as Chief Operating Officer rounding out the executive leadership team.
When did Merck KGaA complete its acquisition of Springworks Therapeutics?
Merck KGaA completed its acquisition of Springworks Therapeutics on July 1, 2025, for an enterprise value of approximately 3.4 billion dollars, adding Springworks' rare oncology portfolio to Merck's healthcare business.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating